Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium

Article English OPEN
Howat, William J ; Blows, Fiona M ; Provenzano, Elena ; Brook, Mark N ; Morris, Lorna ; Gazinska, Patrycja ; Johnson, Nicola ; McDuffus, Leigh‐Anne ; Miller, Jodi ; Sawyer, Elinor J ; Pinder, Sarah ; van Deurzen, Carolien H M ; Jones, Louise ; Sironen, Reijo ; Visscher, Daniel ; Caldas, Carlos ; Daley, Frances ; Coulson, Penny ; Broeks, Annegien ; Sanders, Joyce ; Wesseling, Jelle ; Nevanlinna, Heli ; Fagerholm, Rainer ; Blomqvist, Carl ; Heikkilä, Päivi ; Ali, H Raza ; Dawson, Sarah‐Jane ; Figueroa, Jonine ; Lissowska, Jolanta ; Brinton, Louise ... view all 52 authors (2014)
  • Publisher: John Wiley and Sons Inc.
  • Journal: The Journal of Pathology: Clinical Research, volume 1, issue 1, pages 18-32 (eissn: 2056-4538)
  • Related identifiers: doi: 10.1002/cjp2.3, pmc: PMC4858117
  • Subject: tissue microarrays | 3122 Cancers | breast tumours | Original Article | 3123 Gynaecology and paediatrics | digital pathology | Original Articles | immunohistochemistry | automated scoring

Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standardized scoring methods... View more
  • References (31)
    31 references, page 1 of 4

    1. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10 159 cases from 12 studies. PLoS Med 2010; 7: e1000279.

    2. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011; 29: 4273-4278.

    3. Curtis C, Shah SP, Chin D-F, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.

    4. S rlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.

    5. Perou CM, S rlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.

    6. Wishart GC, Bajdik CD, Dicks E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012; 107: 800-807.

    7. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.

    8. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.

    9. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.

    10. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.

  • Related Research Results (1)
  • Metrics
    views in OpenAIRE
    views in local repository
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    White Rose Research Online - IRUS-UK 0 3